Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
A Randomised Pilot Study on the Acupuncture of Si Guan Xue for the Treatment of Cancer Pain Specialty: Department of Oncology, Guangzhou University of Chinese Medicine Author: Lin Dao Yi (Lam To Yi) Tutor: Professor Lin Li Zhu Abstract Objective To determine the efficacy and safety of acupuncture on si guan xue for treating cancer pain. Design, setting and participant A Randomized Controlled Trial was conducted in the Department of Oncology of the First Affiliated Hospital of Guangzhou University of Chinese Medicine and the OncWell Integrated Cancer Centre in Hong Kong (May 2012 to February 2014). Advanced stage cancer patients (45 patients age from 24 to 91 years old with moderate to severe cancer pain) were treated by Chinese Medicine Practitioners. Intervention The treatment arm was sub-divided into the treatment arm 1 (the si guan xue arm, n=14) and treatment arm 2 (the si guan xue plus commonly used acupoints arm, n=14), while the control arm was the commonly used acupoints arm (n=14). A course of acupuncture treatment consisted of seven treatment sessions, which were delivered to the patients either daily or alternate day. The analyst was blinded to the data analysis. Outcomes and Measures Primary outcomes were efficacy of acupuncture in relieving the cancer pain and patient’s subjective improvement as measured by the Patient Global Impression of Change (PGIC). Secondary outcomes included the assessment by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core (EORTC QLQ-C30) and the Karnofsky's Performance Status (KPS) score. Results Analysis showed cancer pain reduction in treatment arm 2 with the most 1 remarkable improvement on day 5 and 6. Statistically significant improvements in comparison with the control arm(P<0.05). The difference in their PGIC scores was not statistically significant ( P <0.05). Secondary outcomes was no statistically significant difference in all these EORTC QLQ-C30 and KPS score (P>0.05). There was no serious adverse event. Conclusion The study supported the efficacy and safety of acupuncture on si guan xue plus commonly used acupoints for cancer pain management. Further large scale, multi-centers, and randomized controlled trials peculiar to different types of cancer are warranted to confirm its treatment effects in more detail, and to further improve the acupuncture treatment protocol. Key words: Acupuncture ;Si Guan Xue ;Cancer pain ;Randomized controlled trial 2 Cancer,is one the major factors that cause death in the world. According to the recent reports, there were 12.7million people who were newly diagnosed in 2008, and 7.6million people were died because of cancer (13% of all deaths). By predicting,the total number of deaths that caused by cancer would be increased from 13% in 2007 to 45% in 2030. For the newly developed countries, the number would be increased from 11.3 million in 2007 to 15.5 million in 2030〔1〕. Cancer pain is one of the most common symptoms of those suffering from cancer. According to the World Health Organization (WHO), there are 24.6million cancer patients in total, 20% to 30% of them are suffering from different level of pain. The three-step analgesic ladder of WHO is widely used, but there are still a lot of cancer patients (particularly in advanced stages) lack of effective pain control. Many of them may need central nervous analgesics(eg. opioids)for pain control but it may bring many serious side effects,including nausea, vomiting, constipation, dryness of mouth, urinary retention, sleep disturbance,or even confusion, hallucinations, respiratory distress , which bringing intolerance to 〔2-3〕 patients and their families are difficult to cope with . A wide range of indications for acupuncture and show significant effects especially in pain control. It is safe to use, benefits include analgesic effect, rapid onset, long sustained remission, basically no side effects , easy to apply , harmless and no drugs dependence or addiction etc〔4〕. Acupuncture of“si guan xue” , is a very unique combination of acupuncture. “Si guan” was firstly seen in "Twelve of the original nine-pin, Lingshu",indicated that "there are five zang and six Fu, and six fu has twelve original, twelve original proceed from si guan, si guan treating five zang". The famous Chinese Medicine Practitioner of Ming, Yang Jizhou added that: "Si guan, is taichong and hegu." 〔5〕 In the combination of two acupoints, yin and yang, zang and fu, up and down, mainly qi and blood and thus complement each other. Si guan is widely used clinically, the features are highly efficacy, easy to get arrival of qi, 3 acupuncture stimulation is strong, manipulation is simple, safe to use 〔6-7〕 . It is highly recommended for deserving of further study. Methods A randomized clinical trial was conducted. The institutional human ethics committee approved the study. Participants provided written informed consent. We recruited participants from the Department of Oncology of the First Affiliated Hospital of Guangzhou University of Chinese Medicine and the OncWell Integrated Cancer Centre in Hong Kong between May 2012 to February 2014. All patients in this study were confirmed advanced cancer patients in both clinical and pathology, and pain was their chef complaint. Patients’ age from 24 to 91 years old, were well enough and had sufficient proficiency to complete assessment forms. Pain Assessment Form with Numeric rating scale〔8〕is used and the result of Patient Global Impression of Change: PGIC〔9〕 will be assessed. The Pain Assessment Form with Numeric rating scale (NRS) is a 0 to 10 numerical scale (0 = the best, 10 = the worst) to rate severity of pain. 3 sets of EORTC QLQ-C30 〔 10 〕 will be completed by patients:before the starting of study,after completing the 7th acupuncture treatment,and 2 weeks after the treatment in follow-up visiting. Randomization and Blinding Participants initially consented, were recruited and interviewed by trained investigator, who assisted the patient to complete the EORTC QLQ-C30 and pain assessment form. Randomization hidden program is used, a computer random method for encoding〔11〕 and random coding were sealed into the envelopes so as to avoid human intervention. The analyst of this study was blinded to the data analysis. Interventions We used a Chinese Medicine style of acupuncture. Acupuncture was done 4 by the experienced Chinese Medicine Practitioners (9 and 12 years of clinical practice, 3 and 10 years of acupuncture experience) who had completed Bachelor and Master degree in Chinese Medicine (one is Master degree in acupuncture), and well trained in acupuncture. A course of acupuncture treatment consisted of seven treatment sessions, which were delivered to the patients either daily or alternate day. Chinese Medicine Treatments In this study, acupuncture was used for treatment of cancer pain. The common Chinese Medical Diagnosis is combination of deficiency and strength. The strength is including accumulation of qi and blood. The deficiency is including deficiency of qi and blood, ying and yang, and Zang-fu etc. Deficiency is more prominent for advanced cancer patients 〔12-13〕 . The choice of acupoints The treatment arm was sub-divided into the treatment arm 1 (the si guan xue arm) and treatment arm 2 (the si guan xue plus commonly used acupoints arm), while the control arm was the commonly used acupoints arm (the combination of Neiguan, Zusanli and Sanyinjiao xue acupoints chosen, according to the previous literature review〔14-28〕). These acupoints, especially those located below the elbow and knee joints of the Twelve Regular Meridians, have the therapeutic effects on the diseases of the local and the remote regions. Single-use MOCM needles (0.25x25mm or 0.30x40mm) were inserted under skin 10-20mm depth vertically, and then used reinforcing-reducing method to activate the qi until the sensation of arrival of qi (numbness, fullness and heaviness). Patient lying down and needles were left in situ for 30 minutes. A course of acupuncture treatment consisted of seven treatment sessions either daily or alternate day. Statistical Analysis Statistical analysis was performed by PASW Statistic 18.0 (IBM SPSS Inc., Armonk, New York, USA) and SAS 9.2 software (SAS Institute Inc., Cary, USA). Intention-to-treat (ITT) population was the main statistical 5 method in our research. 1. Analysis of efficacy Descriptive analysis : Baseline demographic and clinical characteristics were performed by descriptive analysis. Cross-sectional data analysis:compare the efficacy of the intervention group at some point, using analysis of variance (ANOVA) for pairwise comparison; Longitudinal data analysis:comparison on the effects of different interventions at different times by repeated measures design approach, analysis of the intervention group effect, time effect, intervention and time interaction. 2. Analysis of influencing factors In the main outcomes of cancer pain relief scores as the dependent variable , independent variable is the intervention group , included different demographic, different types of cancer and different clinical centres as controls. Multi-level statistical model was performed with data divided into 2 levels: individual level and group level,or individual level and hospital level. 3. Sensitivity analyzes Per protocol analysis without lost data was performed and compared with results of ITT analysis. Mix-effects model was performed to adjust for baseline covariates and clustering among individuals within a hospital. Analysis of safety By using descriptive analysis, analyze the unsafe events, numbers, symptoms, treatment and consequences. Results Demographic data analysis 1. General Information of patients In between May 2012 to February 2014, 45 numbers of cancer patients were invited. 3 invitees refused to participate in this study because of living 6 far away or unwilling to accept acupuncture. There are only 42 participants, 30 from China and 12 from Hong Kong, randomized into the treatment arm and control arm, 14 for each arm (Figure 1). 7 Patients were invited (n=45) Unwilling patients (n=3) Residing at distant (n=2) Unwilling for acupuncture (n=1) Patients participated (n=42) Treatment Arm Control Arm (n=14) Treatment Arm 1 (n=14) Treatment Arm 2 (n=14) Patients’ condition Patients could not complete Patients could not complete deteriorated and could not treatment (n=5) treatment (n=5) complete treatment (n=2) Not interested (n=3) Not interested (n=1) Condition deteriorated Condition deteriorated (n=2) 死亡 (n=2) (n=4) 死亡 (n=2) Patients completed treatment (n=12) Patients completed treatment (n=9) Patients completed treatment (n=9) Patients completed follow up (n=12) Patients completed follow up (n=8) Patients completed follow up (n=29) Patient Death and could not complete follow up (n=1) 12 patients included 12 patients included 12 patients included in analysis in analysis in analysis Figure 1 Research Flowchart 8 Baseline characteristics of patients were list in Table 1, number of male patient was 20 and female was 22 respectively. For patients in Mainland China, their primary majorly was lung cancer (n=11), and for Hong Kong was head and neck cancer (n=4). Most of the patients were suffering from cancer with stage IV (n=37), and some of them were suffering from another chronic diseases too (n=26) (Table 1). Before treatment, the average pain level was 5.81, according to NRS belonged to moderate pain 〔8〕 . KPS was 70% indicated that they could live independently but could not maintain normal activities or works〔29〕. Table 1 Baseline Characteristics of Patients (n=45) Participants All patients Mainland China General Information Sex Male Female Age Average Range Marital status Single Married Widowed Education Illiteracy Primary school Secondary school High school University or above Primary Disease Site Head and neck Lung Breast Gynecological Liver Upper GI(Oesophagus, stomach and spleen) ) Lower GI(Colon) Others Hong Kong Unwilling Participant HongsKong No. % No. % No. % No. % 20 22 47.62 52.38 15 15 50 50 5 7 41.67 58.33 0 3 0 100 57.59 24-91 56 24-79 59.17 42-91 78.33 74-82 2 38 2 4.76 90.48 4.76 0 30 0 0 100 0 2 8 2 16.67 66.66 16.67 0 2 1 0 67 33 8 13 2 14 5 19.05 30.95 4.76 33.33 11.91 6 12 2 9 1 20 40 6.67 30 3.33 2 1 0 5 4 16.67 8.33 0 41.67 33.33 1 1 0 1 0 33 33 0 33 0 5 12 3 6 5 5 11.9 28.57 7.14 14.29 11.9 11.9 1 11 1 5 5 3 3.33 36.67 3.33 16.67 16.67 10 4 1 2 1 0 2 33.33 8.33 16.67 8.33 0 16.67 1 1 0 0 33 33 0 0 0 0 3 3 7.14 7.14 2 2 6.67 6.66 1 1 8.33 8.34 0 1 0 33 9 Stage of cancer Ⅲ Ⅳ Other chronic diseases Level of pain Average Range KPS score Average Range 5 37 26 11.9 88.1 61.9 1 29 20 3.33 96.67 66.67 4 8 6 33.33 66.67 50 0 3 2 5.81 2-8 5.9 2-8 5.58 5-8 7 5-8 70 40-90 69 40-90 72.5 60-80 70 60-80 2. Information on patients of pain before treatment The minimum number of pain sites for each participant was 1, maximum was 7. There were 90 pain sites totally, most of the pain sites were located on lower limb (n=20) (Table 2). The most intensive average pain in the past 24 hours before treatment is 7.48. According to NRS, it belonged to severe pain. Occurrence of severe pain was 4.74 in average, the average of the minimum pain is 3.1, and mean of pain is 5.62. The average of pain just before the treatment was 5.8, which belonged to moderate pain〔8〕. Table 2 Pretreatment data on site of pain Site of pain Head Neck and shoulder Upper limb Upper back Lower back Chest Upper abdomen Lower abdomen Lower limb Others All patients No. 2 10 8 12 10 8 7 8 20 5 Mainland China No. 0 2 1 8 8 5 5 5 11 2 Hong Kong No. 2 8 7 4 2 3 2 3 9 3 Table 3 Pretreatment data on level of pain in the last 24 hours Level of pain Average of the most severe pain Range Average number on outbreaks of severe pain Range All patients Score 7.48 3-10 4.74 0-9 10 Mainland China Score 7.87 5-10 4.3 1-8 Hong Kong Score 6.5 3-9 5.83 0-9 0 100 67 Average of the slightest pain Range Average of pain Range Average of current pain Range 3.1 0-8 5.62 3-8 5.8 0-9 2.93 0-7 5.73 3-8 5.9 1-8 3.5 0-8 5.33 3-8 5.58 0-9 Analysis of outcome 1. Primary outcome The primary outcome of this study was to evaluate the effectiveness of acupuncture on si guan xue for treating cancer pain. According to the analysis on the seven treatment sessions, the pain relieving score of the treatment arm 1 and control arm had the tendency to decrease. But the treatment arm 2 was increased, especially over the fifth and sixth day of treatment (Table 4) (P<0.05). Therefore, the most effectiveness of acupuncture in relieving the cancer pain was the combination of the si guan xue and commonly used acupoints (Figure 1). Table 4 Changes of cancer pain reduction score among 3 groups Time Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Main effect of time (P-value)* Arm 1 (n=14) 1.93±1.21 1.93±1.14 1.93±1.14 1.43±1.16 1.36±1.01 1.29±1.14 1.36±1.08 Control arm (n=14) 1.36±1.15 1.14±0.77 1.07±1.07 1.21±0.97 0.86±0.86 0.93±0.83 1.00±1.04 >0.05 Arm 2 (n=14) 1.86±1.03 1.57±1.28 1.64±1.22 1.43±1.02 1.79±0.89# 1.79±1.19# 1.29±1.07 P-value 0.36 0.17 0.14 0.83 0.04 0.11 0.65 Note:* There was no interaction among the changing trend over time of pain reduction scores and intervention factor of the three groups. # Compared with the control group, cancer pain reduction scores were statistically significant difference, P<0.05. 11 Cancer pain Reduction score Figure 2 Changes of pain reduction score among 3 groups (Group 1: Arm 1; Group 2:Control group; Group 3:Arm 2) PGIC score is based on the patient's perception of the overall change, it is patient’s subjective efficacy measures. Whereas the results of PGIC measurement across the three arms revealed that the difference in their PGIC scores was not statistically significant (P<0.05)(Table 5). Table 5 PGIC score of 3 groups Time Day 7 Arm 1 (n=14) 2.42±0.79 Control arm (n=14) 2.64±0.67 Arm 2 (n=14) 2.56±0.53 P-value 0.74 2. Secondary outcome Both the Global Health Scale and Functional Scale were increasing during the treatment course (Table 6,7 and Figure 3), whereas the Symptom Scale was decreasing (Table 8). However, there was no statistically significant difference found across the three arms in all these EORTC QLQ-C30 domains(P>0.05). 12 Table 6 Global health score and changes of 3 groups Time Baseline Day 7 Follow up Main effect of time (P-value)* Arm 1 (n=14) 39.88±19.39 50.60±17.13 50.60±19.47 Control arm (n=14) 32.74±18.90 44.64±20.83 45.24±16.89 <0.05 P-value Arm 2 (n=14) 35.12±15.04 48.81±16.62 46.43±18.98 0.57 0.68 0.73 Note:* There was no interaction among the changing trend over time of Global Health scores and intervention factor of the three groups. Global health Figure 3 Global health score and changes of 3 groups (Group 1: Arm 1; Group 2:Control group; Group 3:Arm 2) Table 7 Functional Scale score and changes of 3 groups Time P-value Arm 1 Control arm Arm 2 (n=14) (n=14) (n=14) Baseline 90.29±4.00# 87.24±3.89 88.60±3.56 0.12 Day 7 91.56±4.94 89.21±4.16 90.35±4.10 0.38 Follow up 90.79±4.85 89.78±3.53 90.48±4.27 0.81 Main effect of time <0.05 (P-value)* Note:* There was no interaction among the changing trend over time of Functional scale scores and intervention factor of the three groups. 13 Table 8 Symptom Scale score and changes of 3 groups Time Arm 1 (n=14) 4.46±1.59 3.36±2.39 3.72±2.02 Baseline Day 7 Follow up Main effect of time (P-value)* Control arm (n=14) 5.45±1.88 3.93±1.90 3.91±1.78 <0.05 Arm 2 (n=14) 5.21±1.86 4.17±1.92 4.27±2.10 P-value 0.32 0.57 0.28 Note:* There was no interaction among the changing trend over time of Symptom scale scores and intervention factor of the three groups. KPS score of the three arms showed an increasing trend during the treatment course, but the difference across the three arms was not statistically significant(P>0.05)(Table 9 and Figure 4). Table 9 KPS score and changes of 3 groups Time Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Main effect (P-value)* Arm 1 (n=14) 70.00±15.19 70.00±15.19 70.00±15.19 70.00±15.19 70.71±14.92 70.71±14.92 70.71±14.92 of time Control arm (n=14) 72.86±13.83 72.86±13.83 73.57±13.36 73.57±13.36 73.57±13.36 73.57±13.36 73.57±13.36 <0.05 Arm 2 (n=14) 67.14±9.14 67.14±9.14 67.86±9.75 68.57±9.49 68.57±9.49 68.57±9.49 68.57±9.49 P-value 0.51 0.51 0.51 0.57 0.59 0.59 0.59 Note:* There was no interaction among the changing trend over time of KPS scores and intervention factor of the three groups. 14 KPS score Figure 4 KPS score and changes of 3 groups (Group 1: Arm 1; Group 2:Control group; Group 3:Arm 2) 3. Subgroup analyzes The subgroup analysis shown that the different types of cancer and cancer pain reducing score of different age groups, both have no statistically significant difference(P>0.05), The finding excluded the influence of subgroups,the result was reliable and stable(Table 10 and 11). 15 Table 10 Reduction pain score and changes of different types of cancer of 3 groups Time Lung(n=12) Day 1 1.75±1.36 Day 1 1.50±1.0 Day 1 1.42±1.31 Day 1 1.25±1.22 Day 1 1.50±1.09 Day 1 1.33±0.89 Day 1 1.50±1.17 Main effect of time (P-value)* Gyne(n=6) 2.50±0.55 2.0±1.26 2.0±0.63 1.67±1.03 1.83±1.17 1.50±1.05 1.67±0.82 Liver(n=5) 2.20±1.30 0.80±0.84 1.20±1.10 1.00±0.71 0.80±0.45 1.20±0.45 1.00±0.00 Primary Disease Site Upper GI(n=5) Head & Neck(n=5) 1.00±1.00 2.00±1.41 1.20±1.10 2.80±1.30 1.20±1.30 2.40±1.67 1.40±1.14 2.00±1.22 0.80±0.84 1.80±1.10 0.60±1.34 2.40±1.82 0.40±0.55 1.60±1.67 >0.05 Breast(n=3) 1.00±0.0 1.33±0.58 1.67±1.15 1.33±1.53 1.33±1.53 1.33±1.53 1.33±1.53 Colon(n=3) 1.33±0.58 1.67±0.58 1.67±0.58 1.00±0.00 1.00±0.00 1.00±0.00 0.67±0.58 Others(n=3) 1.00±0.00 0.67±0.58 0.67±0.58 1.00±0.00 1.00±0.00 1.00±0.00 0.67±0.58 P-value 0.26 0.08 0.53 0.82 0.48 0.37 0.38 Note:* There was no interaction among the changing trend over time of cancer reduction pain score on different types of cancers and intervention factor of the three groups. 16 Table 11 Reduction pain score and changes of different age groups of 3 groups Time ≤44(n=10) Day 1 1.70±1.25 Day 1 1.00±0.94 Day 1 1.40±1.17 Day 1 1.60±1.07 Day 1 1.40±0.97 Day 1 1.80±0.92 Day 1 1.70±1.16 Main effect of time (P-value)* 45-59(n=14) 1.93±0.92 1.79±1.19 1.71±0.99 1.43±1.02 1.29±0.99 1.14±0.86 1.21±1.05 60-74(n=12) 1.50±1.24 1.50±1.09 1.42±1.38 1.25±1.06 1.33±1.07 1.17±1.53 1.17±0.94 >0.05 ≥75(n=6) 1.67±1.37 2.00±1.10 1.67±1.37 1.00±1.10 1.33±1.03 1.33±0.82 0.50±0.84 P-value 0.83 0.26 0.89 0.70 1.00 0.49 0.18 Note:* There was no interaction among the changing trend over time of cancer reduction pain score on different age group and intervention factor of the three groups. 4. Sensitivity analyzes According to the analysis of without lost data, per protocol analysis through observation, the combination of si guan xue and commonly used acupoints in the treatment of cancer pain, patients cancer pain relieving scores were gradually increased, especially in the fifth and sixth day, the difference was statistically significant (P <0.05). These results in Table 4 were similar to the results of the ITT analysis, this study also suggested that the ITT analysis results were more stable and reliable (Table 12). 17 Table 12 Reduction pain score and changes of 3 groups per protocol analysis Time Arm 1(n) Day 1 Day 1 Day 1 Day 1 Day 1 Day 1 Day 1 Main effect of time (P-value)* Control arm(n) 1.93±1.21(14) 1.92±1.16(12) 1.92±1.16(12) 1.33±1.15(12) 1.25±0.97(12) 1.17±1.11(12) 1.25±1.06(12) 1.36±1.15(14) 1.14±0.77(14) 1.08±1.12(13) 1.18±0.87(11) 0.73±0.65(11) 0.82±0.60(11) 0.91±0.94(11) >0.05 Arm 2(n) 1.86±1.03(14) 1.54±1.33(13) 1.62±1.26(13) 1.36±1.12(11) 1.82±0.98#(11) 2.00±1.41#(9) 1.22±1.30(9) Note:* There was no interaction among the changing trend over time of pain reduction scores and intervention factor of the three groups. # Compared with the control group, cancer pain reduction scores were statistically significant difference, P<0.05. For mix-effects model, incorporate the effects of baseline and clinical center, these variables had little effect on the outcome, suggested that changes in the primary outcome of this study were mainly caused by the intervention of factors, result was reliable and stable (Table 12). Table 13 Sensitivity analyzes on the primary outcome of different factors Different time point Different types of cancer Different age groups Different centre Molecular degrees of freedom 6 Denominator degrees of freedom 110 F value P-value 1.40 0.22 7 41.9 2.88 0.35 3 41.9 1.00 0.40 1 41.9 2.97 0.09 5. Safety analyzes This study also considered the safety of acupuncture, the side effects of acupuncture included:fainting, hematoma, curved needle, broken needle etc. 18 P-value 0.36 0.22 0.21 0.91 0.02 0.06 0.72 In this study, safety precautions had been done before patients receiving acupuncture treatment. Throughout the study, there were no serious accidents related to acupuncture treatment. Discussion Acupuncture is extremely useful in controlling the pain experienced by many cancer patients. It is a complementary and conservative therapy that traditionally helps to balance the flow of vital energy, which in turn helps to relieve pain. It may be an effective analgesic adjunctive method for cancer patients and its widespread acceptance〔30-32〕. According to the analysis on the seven treatment sessions, the pain relieving score of the treatment arm 1 and control arm had the tendency to reduce. But the treatment arm 2 was increased, especially over the fifth and sixth day of treatment. Therefore, the most effectiveness of acupuncture in relieving the cancer pain was the combination of the si guan xue and commonly used acupoints. A course of acupuncture treatment consisted of fourteen treatment sessions was suggested for further improve the acupuncture treatment protocol〔33〕. The special technique of acupuncture over treatment arm 2 was used. Opening of si guan xue at first and then regulating the commonly used acupoints, is a stronger efficacy mechanism〔34-35〕. There were studies to mention that acupuncture over si guan xue could activate the qi and replenish the vital substances of the body, strengthen the visceral organs etc〔6-7〕 . It would be more effective to control cancer pain. There was no statistically significant difference found across the three arms in the PGIC, EORTC QLQ-C30, and KPS score (P>0.05). According to the manual of EORTC QLQ-C30〔36〕, for Symptom Scale, the higher the score means the more symptoms or problems, which leads to the poor quality of life. EORTC QLQ-C30 scoring showed that the decreased score in symptom area, mean the better quality of life to patients. Some studies show that acupuncture treatment in patients with stage IV cancer symptoms, KPS score of 60%, for Stage III symptoms, KPS score 19 of 70%, indicating that the quality of life has been improved〔37〕. The KPS of this study was 70%, believed that the quality of life of patients had been improved Some studies show that patients with advanced cancer, considering they are late stage cancer, the attrition rate of 40% or less is still acceptable〔38〕. The attrition rate of this study was 28.57%, less than 40%, the effectiveness was still acceptable. Limitation and advantage The main limitation of this study is the small sample size, the representation is not enough to support acupuncture's efficacy in treatment of cancer pain. The second limitation is inadequate treatment time. Some studies considered the longer acupuncture treatment time maybe more effective in controlling cancer pain and improving quality of life of the patients 〔38〕 . During the study,the pain of two patients was reduced after the 2nd acupuncture treatment, and the amount of analgesia was reduced too. When the study was ended, there were 7 patients requested to continue the acupuncture treatment. Shown that acupuncture of si guan xue may help cancer patients to control pain and improve their quality of life. Conclusion The study supported the efficacy and safety of acupuncture on si guan xue plus commonly used acupoints for cancer pain management. Further large scale, multi-centers, and randomized controlled trials peculiar to different types of cancer are warranted to confirm its treatment effects in more detail, and to further improve the acupuncture treatment protocol. Key words: Acupuncture ;Si Guan Xue ;Cancer pain ;Randomized controlled trial 20 Reference [1]World Health Organization. Is the number of cancer patients in the world increasing or decreasing ? http://www.who.int/features/qa/15/zh/index.html , 2013.7.15. [2]Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management: Stepping up the quality of its evaluation[J]. The Journal of the American Medical Association,1995,274(23):1870-1873. [3]Cherny NI. The Management of Cancer Pain[J]. CA—A Cancer Journal for Clinicians, 2000,50(2):72-73. [4]Johnstone PAS, Polston GR, Martin PJ. Integration of acupuncture into the oncology clinic[J]. Palliative Medicine,2002,16:235-239. [5]Jin Yin, Huang Longxiang. Yang Jizhou "The culmination of Acupuncture"[M]. Beijing: People's Medical Publishing House,2010,7:47. [6]Tao Geng. Meta clinical experience of si guan xue[J]. Journal of Inner Mongolia Traditional Chinese Medicine,2007,9:49-51. [7]Huan Jing, Chun Liu. Clinical application of si guan xue[J]. Journal of Jilin Traditional Chinese Medicine,2005,25(4):34. [8]National Institutes of Health: Warren Grant Magnuson Clinical Center. Pain Intensity Instruments. http://www.mvltca.net/Presentations/mvltca.pdf, 2003,7. [9]Farrar JT, Young Jr. JP, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale[J]. Pain, 2001, 94: 149–158. [10]EORTC Quality of Life Department. The Chinese version of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core (EORTC QLQ-C30). http://www.eortc.be/home/qol/files/C30/QLQ-C30%20Chinese%20Mandarin%20Simplifie d.pdf,2012.1.7. [11]Urbaniak GC,Plous S. Research Randomizer (Version 4.0) [Computer software]. http://www.randomizer.org//form.htm,2013.6.22. [12]Zhanwen Liu, Liang Liu. Essentials of Chinese Medicine[J]. New York : Springer-Verlag London Limited,2009(1):284-288. [13]Yanfen Li, Wenbin Fu. Pain caused by healthy Qi deficiency and its management with moxibustion[M]. Hong Kong : Proceedings of the International Academic Seminar of Acumoxa in Pain Management,2009,5:355-358. [14]Wenqi Zhang. Acupuncture treatment of cancer pain in 160 cases[J]. Emergency of Chinese Medicine of China,2008,17(4):543-544. [15]Zhan Gao, Xiaohuang, Xu Ben Qiang Rao, et al. Clinical observation on the efficacy of combination of acupuncture and topical treatment of cancer pain[J]. Practical Journal of Chinese Medicine,1998,11:7. [16]Jinhua Xu. The combination of electroacupuncture with the three-step analgesia 21 for the treatment of cancer pain in 15 cases[J]. Shanghai Journal of Acupuncture, 1999,18(5):21. [17]Guiping Chen, Jinhong Yang, Mei Juan Yu, et al. Acupuncture treatment of radiotherapy and chemotherapy gastrointestinal reactions in 44 cases[J]. Chinese acupuncture and moxibustion,1996,16(7):9. [18]Rong Mu, Qu Bin Zheng, Wei Zhu Yang, et al. Observation on therapeutic effect of acupuncture of Neiguan in complications of interventional treatment on hepatic carcinoma[J]. Chinese Journal of Integrated Chinese and Western Medicine,1995, 16(10):611. [19]Wen Dong, Jiebin Yang. Observation on acupuncture analgesic effect of cancer pain[J]. Practical Journal of Chinese Medicine,1999,15(7):28. [20]Li Deng. Acupuncture treatment of hepatocellular carcinoma after interventional Chemotherapy induced hiccups [J]. Shanxi Chinese Medicine,1997,13(2):42. [21]Yu Dan. The clinical study of acupuncture of analgesic effect on cancer pain[J]. Chinese acupuncture and moxibustion,1998,1(18):17. [22]Ronghua Bian. The clinical study of acupuncture treatment on cancer pain of stomach cancer[J]. Journal of Chinese Medicine,1995,36(5):277-280. [23]Bin Wu, Rongxing Zhou Kuang He. Research status and prospects of acupuncture and moxibustion regulating immunological function [J]. Shanghai Journal of Acupuncture and moxibustion,1999,18(1):46. [24]Xionghua Chen. Clinical and experimental research survey of acupuncture and moxibustion on antitumor effect[J]. Hubei Journal of Chinese Medicine,1998,5: 59. [25]Xiaoling Gao. Observation on the therapeutic effect and nursing care of acupuncture combined with three step analgesic ladder treatment of cancer pain[J]. Modern Nursing,2002,8(8):588. [26]Sun YL, Yu LR. Observation on therapeutic effect of needle-retaining method of triple acupuncture in 80 cases of pain due to liver cancer[J]. Chin Acupuc Moxibustion,2000,21:211-212. [27]Lee H, Schmidt K, Ernst E. Acupuncture for the relief of cancer-related pain: a systematic review[J]. European Journal of Pain,2005,9:437-444. [28]Peng H, Peng FD, Xu L, et al. Efficacy of acupuncture in treatment of cancer pain: a systematic review[J]. Chinese Journal of Integrative Medicine, 2010, 8: 501-509. [29]Karnofsky DA, Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod CM (Ed). Evaluation of Chemotherapeutic Agents[M]. New York: Columbia University Press,1949:196. [30]Steven Aung. The clinical use of acupuncture in oncology : symptom control[J]. Acupunct Med,1994,12:37-40. [31]Hyangsook Lee, Katja Schmidt, Edzard Ernst. Acupuncture for the relief of 22 cancer-related pain – a systematic review[J]. European Journal of Pain, 2005,8;9(4):437-444. [32]Johnstone PA, Polston GR, Niemtzow RC, Martin PJ. Integration of acupuncture into the oncology clinic. Palliat Med,2002,16(3):235-239. [33]Choi T, Lee MS, Kim T. Acupuncture for the treatment of cancer pain: a systematic review of randomized clinical trials[J]. Supportive Care in Cancer,2012,20:1147-1158. [34]Xiong Ming. Experience on clinical application “si guan xue”[J]. Practical Journal of Chinese Medicine,2006,22(5):300. [35]YuJie Jia. Preliminary knowledge on opening of si guan xue[J].Chinese Medicine of Shanxi,2008,29(8):1103-1104. [36]QL Coordinator, Quality of Life Unit, EORTC Data Center. EORTC QLQ-C30 Scoring Manual (3rd Edition). http://www.eortc.be/qol/files/SCManualQLQ-C30.pdf, 2012.1.7. [37]Cho WCS. Supportive Cancer Care with Chinese Medicine[M]. London: Springer Science+Business Media,2010:29. [38]Follwell M, Burman D, Le LW, et al. Phase II Study of an Outpatient Palliative Care Intervention in Patients with Metastatic Cancer[J]. Journal of Clinical Oncology, 2009, 27(2): 206-213. 23